Becton Dickinson & Co
BDX- Exchange
- NYSE
- Industry
- Surgical & Medical Instruments & Apparatus
- SEC CIK
- 0000010795
In the last 90 days, Becton Dickinson & Co insiders filed 0 open-market purchases and 4 sales; 1,446 institutions reported holding it in 13F filings for Q2 2026, worth $41.2B in total; superinvestors Greenhaven Associates and Harris Associates (Oakmark) hold it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Becton Dickinson & Co insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 4 filings
- 3 insiders, $1.25M in total
- Insiders trading
- 3
- Net value
- −$1.25M
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Becton Dickinson & Co, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Roque Vitor | EVP & Chief Financial Officer | 8,041 | Sep 3, 2026 | 3 |
| Feld Michael | EVP, Chief Revenue Officer | 19,720 | Aug 27, 2026 | 14 |
| Polen Thomas E Jr | Chairman, CEO and President | 110,163 | Aug 14, 2026 | 3 |
| Goette Roland | EVP and President, EMEA | 14,856 | Aug 12, 2026 | 2 |
| Huffines Robert Luther | Director | 1,279 | Aug 6, 2026 | 5 |
| Byington Carrie L | Director | 5,018 | Aug 6, 2026 | 5 |
| Muhsin Bilal | EVP & President Connected Care | 41,359 | Jul 6, 2026 | 2 |
| Garrison Michael David | EVP & Pres Med.Essntl&BioPharm | 13,172 | Jun 25, 2026 | 5 |
| Menziuso Peter | EVP and President, BDI | 14,258 | Jun 2, 2026 | 1 |
| Neal Shana Carol | EVP and Chief People Officer | 23,966 | Apr 6, 2026 | 2 |
| Minnix Lanesha | EVP and General Counsel | 7,492 | Mar 17, 2026 | 1 |
| Spikner Pamela L. | SVP Controller & CAO | 3,323 | Mar 4, 2026 | 3 |
| Scott Bertram L | Director | 36,763 | Feb 18, 2026 | 3 |
| Jones Christopher Ian Montague | Director | 24,304 | Feb 5, 2026 | 3 |
| Ring Timothy M | Director | 59,160 | Jan 29, 2026 | 1 |
| Eckert R Andrew | Director | 10,423 | Jan 29, 2026 | 1 |
| Hayes Gregory | Director | 7,159 | Jan 29, 2026 | 1 |
| Henderson Jeffrey William | Director | 9,143 | Jan 29, 2026 | 1 |
| Brown William M | Director | 4,663 | Jan 29, 2026 | 1 |
| Wright Jacqueline | Director | 1,279 | Jan 29, 2026 | 2 |
| Waldstreicher Joanne | Director | 3,391 | Jan 29, 2026 | 1 |
| Shan David | EVP and Chief ISC Officer | 8,926 | Jan 6, 2026 | 2 |
| DelOrefice Christopher | EVP & Chief Financial Officer | 22,982 | Dec 1, 2025 | 1 |
| Mocherla Pavan Kumar | EVP & President, Greater Asia | 5,763 | Dec 1, 2025 | 1 |
| Byrd Richard | EVP & President Interventional | 13,849 | Dec 1, 2025 | 1 |
| Fraser Claire | Director | 22,226 | Sep 11, 2025 | 0 |
| Burzik Catherine M | Director | 14,264 | Jan 30, 2025 | 0 |
| Quinn Michelle | EVP and General Counsel | 6,927 | Dec 3, 2024 | 0 |
| Ezell Antoine C | EVP, President Americas & CMO | 11,970 | Nov 29, 2024 | 0 |
| Spoerel Thomas J | SVPController & Chief Acct Off | 1,928 | Jul 2, 2024 | 0 |
| Hickey David | EVP & President, Life Sciences | 5,862 | Nov 28, 2023 | 0 |
| Larsen Marshall O | Director | 28,919 | Jan 26, 2023 | 0 |
| Khichi Samrat S. | EVP and General Counsel | 9,251 | Jan 5, 2023 | 0 |
| Grover Rishi | EVP and Chief ISC Officer | 9,439 | Jul 12, 2022 | 0 |
| Lim James C | Executive Vice President | 23,941 | Jun 24, 2022 | 0 |
| Larson Betty D | EVP HR & CHRO | 5,872 | Feb 28, 2022 | 0 |
| Campion Simon D | EVP and Segment President | 10,319 | Feb 14, 2022 | 0 |
| Conroy Alexandre | EVP of Integrated Supply Chain | 21,260 | Feb 7, 2022 | 0 |
| Melcher David F | Director | 6,180 | Jan 27, 2022 | 0 |
| Pomeroy Claire | Director | 9,982 | Jan 26, 2022 | 0 |
| Reidy Christopher R | CFO and EVP of Administration | 31,524 | Nov 30, 2021 | 0 |
| Mas Ribo Alberto | EVP and Pres, Life Sciences | 11,662 | Nov 30, 2021 | 0 |
| Rimel Rebecca W | Director | 10,618 | Sep 8, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 26, 2025 (view filing) | Aug 22 | 4 days | Feld MichaelEVP & President, Life Sciences | SSale | −57 | $197.99 | −$11.3K | −0.7%8.36K after | 10b5-1 |
| Sep 11, 2025 (view filing) | Sep 10 | 1 day | Fraser ClaireDirector | SSale | −917 | $187.50 | −$171.9K | −4.0%22.2K after | |
| Sep 29, 2025 (view filing) | Sep 26 | 3 days | Feld MichaelEVP & President, Life Sciences | SSale | −58 | $181.03 | −$10.5K | −0.7%8.30K after | 10b5-1 |
| Oct 28, 2025 (view filing) | Oct 27 | 1 day | Feld MichaelEVP & President, Life Sciences | SSale | −57 | $186.01 | −$10.6K | −0.7%8.24K after | 10b5-1 |
| Nov 7, 2025 (view filing) | Nov 7 | Same day | Scott Bertram LDirector | SSale | −217 | $176.58 | −$38.3K | −0.6%35.8K after | |
| Dec 2, 2025 (view filing) | Dec 1 | 1 day | Feld MichaelEVP, CRO & Pres. Life Sciences | SSale | −75 | $193.36 | −$14.5K | −0.5%16.6K after | 10b5-1 |
| Dec 17, 2025 (view filing) | Dec 17 | Same day | Garrison Michael DavidEVP & Pres Med.Essntl&BioPharm | SSale | −629 | $196.03 | −$123.3K | −4.6%13.1K after | 10b5-1 |
| Dec 29, 2025 (view filing) | Dec 26 | 3 days | Feld MichaelEVP, CRO & Pres. Life Sciences | SSale | −74 | $196.08 | −$14.5K | −0.4%16.5K after | 10b5-1 |
| Jan 16, 2026 (view filing) | Jan 15 | 1 day | Garrison Michael DavidEVP & Pres Med.Essntl&BioPharm | SSale | −1.61K | $207.46 | −$334.0K | −11.7%12.1K after | 2 lots10b5-1 |
| Jan 28, 2026 (view filing) | Jan 26 | 2 days | Feld MichaelEVP, CRO & Pres. Life Sciences | SSale | −75 | $202.73 | −$15.2K | −0.5%16.4K after | 10b5-1 |
| Feb 18, 2026 (view filing) | Feb 18 | Same day | Scott Bertram LDirector | SSale | −953 | $182.61 | −$174.0K | −2.5%36.8K after | |
| Feb 27, 2026 (view filing) | Feb 26 | 1 day | Feld MichaelEVP, Chief Revenue Officer | SSale | −75 | $181.84 | −$13.6K | −0.4%21.3K after | 10b5-1 |
| Mar 27, 2026 (view filing) | Mar 26 | 1 day | Feld MichaelEVP, Chief Revenue Officer | SSale | −75 | $156.83 | −$11.8K | −0.4%21.2K after | 10b5-1 |
| Apr 28, 2026 (view filing) | Apr 27 | 1 day | Feld MichaelEVP, Chief Revenue Officer | SSale | −74 | $151.94 | −$11.2K | −0.3%21.2K after | 10b5-1 |
| May 27, 2026 (view filing) | May 26 | 1 day | Feld MichaelEVP, Chief Revenue Officer | SSale | −75 | $147.35 | −$11.1K | −0.4%21.1K after | 10b5-1 |
| Jun 3, 2026 (view filing) | Jun 1 | 2 days | Polen Thomas E JrChairman, CEO and President | SSale | −2.76K | $146.35 | −$404.5K | −2.4%110.2K after | 10b5-1 |
| Jun 11, 2026 (view filing) | Jun 10 | 1 day | Garrison Michael DavidEVP & Pres Med.Essntl&BioPharm | SSale | −1.10K | $151.48 | −$166.6K | −7.2%14.3K after | 10b5-1 |
| Jun 25, 2026 (view filing) | Jun 24 | 1 day | Garrison Michael DavidEVP & Pres Med.Essntl&BioPharm | SSale | −1.10K | $145.66 | −$160.2K | −7.7%13.2K after | 10b5-1 |
| Jun 26, 2026 (view filing) | Jun 26 | Same day | Feld MichaelEVP, Chief Revenue Officer | SSale | −75 | $152.80 | −$11.5K | −0.4%21.0K after | 10b5-1 |
| Jul 28, 2026 (view filing)11:16 AM ET | Jul 27 | 1 day | Feld MichaelEVP, Chief Revenue Officer | SSale | −75 | $157.13 | −$11.8K | −0.4%20.9K after | 10b5-1 |
| Aug 12, 2026 (view filing)5:27 PM ET | Aug 11 | 1 day | Goette RolandEVP and President, EMEA | SSale | −2.44K | $180.84 | −$440.9K | −14.1%14.9K after | |
| Aug 14, 2026 (view filing)4:36 PM ET | Aug 13 | 1 day | Polen Thomas E JrChairman, CEO and President | SSale | −4.15K | $185.00 | −$768.1K | −3.6%110.2K after | 10b5-1 |
| Aug 27, 2026 (view filing)4:28 PM ET | Aug 26 | 1 day | Feld MichaelEVP, Chief Revenue Officer | SSale | −165 | $188.49 | −$31.1K | −0.8%19.7K after | 10b5-1 |